Skip to content
Home/Companies/Biotech/Stayble Therapeutics

Stayble Therapeutics

Biotech·Sweden·Active·10yr hold
Entry
2016
Hold
10yr
Status
Active

Who owns Stayble Therapeutics?

Stayble Therapeutics is a Swedish Biotech company, currently owned by Chalmers Ventures since 2016.

Hand-verified · updated 2026-08-17

Open JSON · CC-BY
Chalmers Ventures
Investor
Chalmers Ventures
Chalmers Ventures · 2015 · VC

Key facts

HQSweden
SectorBiotech
StatusActive

More from Chalmers Ventures

Other portfolio companies in the same fund.

Adsorbi
Active
ClimateTechSweden· 2023
Compular
Active
Deep TechSweden· 2022
Melt&Marble
Active
FoodTechSweden· 2021
Amferia
Active
MedTechSweden· 2020
Yolean
Active
SaaSSweden· 2020
Aqua Robur
Active
ClimateTechSweden· 2018

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Stayble Therapeutics?

Stayble Therapeutics is currently owned by Chalmers Ventures, through Chalmers Ventures, since 2016.

When did Chalmers Ventures acquire Stayble Therapeutics?

Chalmers Ventures acquired Stayble Therapeutics in 2016.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue